The Kiteworks research reveals that 27% of life organizations acknowledge that more than 30% of their AI-processed data ...

EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6. The expansion cohort for pancreatic ductal ...

The Experimental Drug Development Center (EDDC), Singapore's national platform for drug discovery and development, has announced the presentation of updated clinical data for the ongoing Phase I ...

Clinical trials for drug development are becoming increasingly complex, with numerous variables that must be identified and defined from the start. This complexity arises from rigorous study ...

Addressing protein aggregation, product stability, supply chains, and regulations requires multiple tools, including ...

It’s no secret that drug development is a huge gamble for pharmaceutical companies. The process involves betting billions of dollars and more than a decade of time that a compound will beat the ...

He is an accomplished business development professional with a holistic view of drug development. With over 25 years of experience driving strategic partnerships, business agreements and early product ...

Assessing the distribution of a medication in the brain is critical for the treatment of a vast range of neurological ...

"We are thrilled to join with GATC to create a much improved AI-driven paradigm of drug discovery and development. Studies predict AI technologies could create as much as $350 to $400 billion in value ...